Bio Green Med Solution Inc - Company Profile
Powered by 
All the sales intelligence you need on Bio Green Med Solution Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bio Green Med Solution Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bio Green Med Solution Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Bio Green Med Solution Inc (BGMS), formerly Cyclacel Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that focuses on developing cancer medicines. The company develops drug candidates targeting the cell cycle, transcriptional regulation, epigenetics, and mitosis biology. Its major products include fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor, aimed at treating solid tumors and hematological malignancies. The company collaborates with cancer research organizations such as MD Anderson Cancer Center and Dana Farber Cancer Institute to enhance its clinical programs. BGMS is headquartered in Kuala Lumpur, Malaysia.
Headquarters
Malaysia
Address
Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Kuala Lumpur (Federal Territory of), 59200
Website
www.cyclacel.com
Telephone
1 908 5177330
No of Employees
12
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BGMS (NASD)
Revenue (2024)
$747,000
1637.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
73.3%
(2024 vs 2023)
Market Cap*
$6.0M
Net Profit Margin (2024)
XYZ
98.5%
(2024 vs 2023)
* As of and is in US$
Bio Green Med Solution Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Cyclacel |
| Fadraciclib CDK Inhibitor (Oral) - Solid Tumors, Leukemias, AML/MDS | |
| Plogosertib (oral) - Solid Tumors, Leukemias |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Asset Disposal | In October, the company sold the assets and rights of Plogosertib to Tethra Biosciences, a biotechnology company. |
| 2025 | Acquisitions/Mergers/Takeovers | In September, the company acquired Fitters Sdn Bhd from FITTERS Diversified Berhad, an investment holding company. |
| 2025 | Contracts/Agreements | In January, the company signed a securities purchase agreement with David Lazar to acquire from the Company 1,000,000 shares of Series C Convertible Preferred Stock and 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel. |
Competitor Comparison
| Key Parameters | Bio Green Med Solution Inc | Merck & Co Inc | GSK plc | Traws Pharma Inc | Cardiff Oncology Inc |
|---|---|---|---|---|---|
| Headquarters | Malaysia | United States of America | United Kingdom | United States of America | United States of America |
| City | Kuala Lumpur | Rahway | London | Newtown Square | San Diego |
| State/Province | Kuala Lumpur (Federal Territory of) | New Jersey | England | Pennsylvania | California |
| No. of Employees | 12 | 75,000 | 66,841 | 4 | 31 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Datuk Wong Sing Ee | Chief Executive Officer; Director | Executive Board | 2025 | 44 |
| Kiu Cu Seng | Chief Financial Officer; Director; Secretary | Executive Board | 2025 | 37 |
| Soon Ping Pappas | Director | Non Executive Board | 2025 | 35 |
| Inigo Angel Laurduraj | Director | Non Executive Board | 2025 | 41 |
| Satis Waran Nair Krishnan | Director | Non Executive Board | - | 40 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer